Core Insights - IDEXX Laboratories has launched the IDEXX Cancer Dx Panel in the UK for early detection of canine lymphoma, with a starting price of £22.50 and results available within 3-5 business days [1][5][10] Group 1: Product Details - The IDEXX Cancer Dx Panel is designed to be integrated into existing veterinary workflows, allowing for a single blood draw to be added to diagnostic and wellness panels [5][6] - The test boasts a sensitivity of 79% and specificity of 99%, providing reliable results for both sick and at-risk dogs [5][6] - The test can detect lymphoma signals up to eight months before clinical signs appear, enabling earlier intervention [4][6] Group 2: Market Demand and Impact - Cancer is a leading cause of death in dogs, with 1 in 4 dogs expected to be diagnosed with cancer in their lifetime, and lymphoma accounts for nearly 25% of new cancer diagnoses [2][3] - Research indicates that 71% of pet owners in the UK are interested in cancer screening for their pets, highlighting a strong demand for proactive wellness care [3] - Since its launch in North America in 2025, nearly 6,000 veterinary practices have adopted the test, demonstrating its growing acceptance in the veterinary community [4] Group 3: Future Plans - IDEXX plans to expand the Cancer Dx Panel over the next three years to cover the majority of canine cancer cases, aiming to transform cancer detection and enable earlier interventions [7]